Ferumoxytol
- Generic Name
- Ferumoxytol
- Brand Names
- Feraheme
- Drug Type
- Small Molecule
- Chemical Formula
- Fe3O4
- CAS Number
- 722492-56-0
- Unique Ingredient Identifier
- G6N3J05W84
- Background
Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) .
It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively high dose by rapid intravenous injection .
- Indication
This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron or
who have chronic kidney disease (CKD) .
- Associated Conditions
- Iron Deficiency Anemia (IDA)
- Associated Therapies
- -
Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 50
- Registration Number
- NCT06483061
- Locations
- 🇨🇦
Peter S. Allen MRI Unit, Edmonton, Alberta, Canada
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
- Conditions
- Malignant Solid Neoplasm
- Interventions
- Drug: FerumoxytolDrug: Irinotecan SucrosofateOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingDrug: Veliparib
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT02631733
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸NCI - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
- Conditions
- Bladder CancerKidney CancerProstate Cancer
- Interventions
- Drug: FerumoxytolDiagnostic Test: Magnetic Resonance Imaging (MRI)
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT02141490
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
DCE MRI in Patients With Pancreatic Cancer
- Conditions
- Familial Pancreatic CancerPancreatic AdenocarcinomaPancreatic Intraductal Papillary-Mucinous Neoplasm
- Interventions
- Procedure: Dynamic Contrast-Enhanced Magnetic Resonance ImagingDrug: Ferumoxytol
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 77
- Registration Number
- NCT02070705
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT01296139
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.